CME Group

CME · NASDAQ

$295.31+$1.78 (+0.61%)TodayMarket closed ·
Prev close $293.53

CME analyst rating

HoldConsensus of 15 analysts over the last 12 months. 47% rate it a buy.
  • Strong buy0
  • Buy7
  • Hold6
  • Underperform2
  • Sell0

12-month price target · 17 analysts

Average $291.61 (−1.3% downside)

Low
$232.30
Now
$295.31
High
$346.50

Upgrades and downgrades

The latest rating actions, newest first

CME analyst upgrades, downgrades and rating actions
FirmDateActionRating
Wells FargoOct 14, 2026MaintainsOverweight
Morgan StanleyOct 9, 2026MaintainsOverweight
BarclaysOct 7, 2026MaintainsEqual-Weight
UBSOct 5, 2026MaintainsNeutral
TD CowenOct 5, 2026MaintainsBuy
Wells FargoOct 2, 2026InitiatesOverweight
TD CowenSep 28, 2026MaintainsBuy
TD CowenSep 3, 2026MaintainsBuy
Deutsche BankAug 19, 2026DowngradeBuy → Hold
JP MorganJul 23, 2026MaintainsUnderweight

The case for and against

Updated Oct 14, 2026

Bull case

CME Group is well positioned for durable fundamental outperformance because its core exchange franchise continues to show strong volume momentum, with September ADV tracking about 9% above model and August ADV of 29.7M rising ~6% year over year while open interest climbed ~200 bps year over year, supporting the view that activity can keep compounding. Its growth mix is broadening beyond the institutional base, with retail penetration, single stock futures, weekend metals trading, Treasury clearing, and compute futures creating new demand streams, while a 2% pricing increase in rates and lower perceived FMX risk reinforce pricing power. Additional upside comes from high incremental margins, expected buybacks, and the 27% stake in S&P Dow Jones Indexes, which should lift non-operating income and help sustain strong earnings growth and capital return.

Bear case

CME Group is viewed negatively because its core earnings drivers depend heavily on trading volumes and revenue per contract, both of which face pressure if Average Daily Volume decelerates or pricing weakens. The business also looks vulnerable to macro headwinds such as lower short-term rate expectations, a flatter forward yield curve, and wider credit spreads, which would reduce hedging demand across rates, credit, and energy products. Even with de novo growth and share repurchases supported by the remaining OSTTRA proceeds of $1.55B, the thesis is constrained by market-share risk from new entrants like FMX, CBOE, and ICE, as well as the possibility of poor deal execution and regulatory change.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.